CHRONIC LYMPHOCYTIC
LEUKEMIA (CLL)

Exploring dysfunctional pathways, mechanisms, and biomarkers in CLL to
discover new insights into the progression of the disease.¹

of leukemia cases diagnosed globally are CLL.²

of patients with CLL overexpress the BCL-2 protein.³

INCIDENCE AND MORTALITY

An estimated 18,740 people in the US were diagnosed during 2023, and 4,490 people died from the disease.¹⁵
Five-year survival rate is 88.0% in the US.¹⁵
CLL is most frequently diagnosed among people aged 65 to 74 years ¹⁵
In the US, 98% of CLL cases are diagnosed in people older than 44 years.¹⁵
The median age at diagnosis is 70 years.¹⁵

CLL is a slow-progressing cancer in which mature clonal B lymphocytes accumulate in the bone marrow, blood, and other lymphoid tissues.

Complications associated with CLL include recurrent infection and autoimmune diseases, risk of secondary malignancy, and transformation to diffuse large B-cell lymphoma (DLBCL).⁴

CLL is a slow-progressing cancer in which mature clonal B lymphocytes accumulate in the bone marrow, blood, and other lymphoid tissues.

Complications associated with CLL include recurrent infection and autoimmune diseases, risk of secondary malignancy, and transformation to diffuse large B-cell lymphoma (DLBCL).⁴

CLL is a slow-progressing cancer in which mature clonal B lymphocytes accumulate in the bone marrow, blood, and other lymphoid tissues.

Complications associated with CLL include recurrent infection and autoimmune diseases, risk of secondary malignancy, and transformation to diffuse large B-cell lymphoma (DLBCL).⁴

CLL is a slow-progressing cancer in which mature clonal B lymphocytes accumulate in the bone marrow, blood, and other lymphoid tissues.

Complications associated with CLL include recurrent infection and autoimmune diseases, risk of secondary malignancy, and transformation to diffuse large B-cell lymphoma (DLBCL).⁴

CLL is a slow-progressing cancer in which mature clonal B lymphocytes accumulate in the bone marrow, blood, and other lymphoid tissues.

Complications associated with CLL include recurrent infection and autoimmune diseases, risk of secondary malignancy, and transformation to diffuse large B-cell lymphoma (DLBCL).⁴

Relevant Cancer Targets

BCL-2

Learn about how BCL-2 plays a role in tumor survival and is a rational target for therapeutic intervention.^_MORE>

BTK

Learn about BTK and B cell signaling. ^_MORE^_>

MALT1

Learn about MALT1 and NF-κB signaling. ^_MORE^_>

CD3xCD20 BISPECIFICS

Learn about CD3 on T cells and bispecific targeting of CD20. ^_MORE^_>

CD19

Learn about CD19 and B cell signaling. ^_MORE^_>

Anderson MA, Huang D, Roberts A. Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol. 2014;51(3):219-227.
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4):524-548
Howlader N, Noone AM, Krapcho M, et al (eds). National Cancer Institute. SEER Cancer Statistics Review, 1975-2017. Updated April 2020 based on November 2019 SEER data submission. Accessed March 2024. https://seer.cancer.gov/csr/1975_2017/.
Stilgenbauer S, Furman RR, Zent CS. Management of chronic lymphocytic leukemia. Am Soc Clin Oncol Educ Book. 2015:164-175.
Zhang S, Kipps TJ. The pathogenesis of chronic lymphocytic leukemia. Annu Rev Pathol. 2014;9:103-118.
Guieze R, Wu CJ. Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood. 2015;23:445-453.
Hamblin TJ, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-1854.
Hallek M, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 ;131(25):2745-2760.
Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123(21):3247-3254.
Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
Bewarder M, et al. Current Treatment Options in CLL. Cancers (Basel). 2021;13(10):2468.
Davids MS. How should we sequence and combine novel therapies in CLL? Hematology Am Soc Hematol Educ Program. 2017 ;2017(1):346-353.
Bose P, Gandhi V. Recent therapeutic advances in chronic lymphocytic leukemia. F1000Res. 2017;6:1924.
Lu K, Wang X. Therapeutic advancement of chronic lymphocytic leukemia. J Hematol Oncol. 2012;5(55).
NCI. Cancer Stat Facts: Chronic Lymphocytic Leukemia (CLL).Accessed March 2024.
Scarfo L. Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax. Hematology Am Soc Hematol Educ Program (2022) 2022 (1): 316–322.